<DOC>
	<DOCNO>NCT01849692</DOCNO>
	<brief_summary>The purpose study demonstrate treatment effect ESBA1008 apply microvolume injection infusion retinal function morphology subject exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>ESBA1008 Microvolume Study</brief_title>
	<detailed_description>This 4-cohort study conduct 2 stage . Stage 1 consist 2 Cohorts . In cohort subject randomize 10:3 either receive ESBA1008 ( Cohort 1 : 2 injection , Cohort 2 : 1 infusion 1 injection ) 2 Lucentis injection . Stage 2 conduct similarly different dose level ESBA1008 ( Cohort 3 4 ) . Subjects follow-up visit Day 7 Day 14 . All cohort receive ESBA1008 Day 0 also receive ESBA1008 6mg/50 μL via injection Day 28 . After Day 28 visit ( cohort ) , subject return follow visit Day 42 Day 56 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Sign inform consent document ; Able make require study visit follow instruction ; Agerelated macular degeneration study eye ; Visual acuity within protocolspecified range ; 340 μm minimal central subfield thickness ( CSFT ; Spectralis Equivalent ) Other protocoldefined inclusion criterion may apply . Both eye : Any active infection inflammation ; Study eye : Any treatment exudative agerelated macular degeneration ( AMD ) vitamin supplement ; Study eye : Any current history macular retinal disease ; Study eye : Any concurrent intraocular condition cataract diabetic retinopathy , opinion Investigator , could either require medical surgical intervention course study prevent treat visual loss ; Study eye : Other ocular condition disease , opinion Investigator , could compromise visual acuity ; Study Eye : Uncontrolled glaucoma ; History medical condition , opinion Investigator , would preclude schedule study visit , completion study , safe administration investigational product ; Women childbearing potential lactating , pregnant , plan become pregnant , use adequate birth control method duration study ; Intraocular surgery within 3 month baseline ; Study eye : Any history current evidence retinal angiomatous proliferation ( RAP ) lesion base clinical exam ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Exudative Age-Related Macular Degeneration</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Choroidal neovascularization ( CNV )</keyword>
	<keyword>Vascular endothelial growth factor ( VEGF )</keyword>
</DOC>